"The decision to double numbers in the LuPIN trial at St Vincent’s (at considerable expense to Noxopharm) indicates that Veyonda significantly improves the performance of LuPSMA."
No it indicates that those who control the money strings on the investigation side of the study were not happy to foot the bill for the next extension and most likely permission was struck only if NOX pays for it. Original the study was sheeted for 30 and went ahead at 16 (NOX i believe did not have to pay for those 16 as it does now have to pay for the next round). And in last years AGM the extension study was already penned as a go ahead without any results.
If nox66 did significantly improves performance of LuPSMA and NOX knew about it one thing we all know with NOX is that sort information would not be kept secret lol. Gee the released a Milestone ASX ann so early in the trial with just some lame good news about PSA levels........
(20min delay)
